3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumor
4
Solid Tumor
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Melanoma
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumour
2
Unresectable Stage III Non-small Cell Lung Cancer
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Simpson-Golabi-Behmel syndrome
1
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
Interventions
Pemetrexed
5
Carboplatin
5
pembrolizumab
4
Nivolumab
4
Cisplatin
4
fludarabine
3
Ipilimumab
3
Cyclophosphamide
3
Radiotherapy, Intensity-Modulated
2
Cerebral Decortication
2
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
avelumab
1
atezolizumab
1
Platinum
1
LY2940680
1
Influenza Vaccines
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Blood Component Removal
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
tislelizumab
×
90 days
×
Clear all
No trials found.